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Multiple acyl-CoA dehydrogenase deficiencies (MADDs) are a heterogeneous group of metabolic disorders with combined respiratory-
chain deficiency and a neuromuscular phenotype. Despite recent advances in understanding the genetic basis of MADD, a number of
cases remain unexplained. Here, we report clinically relevant variants in FLAD1, which encodes FAD synthase (FADS), as the cause of
MADD and respiratory-chain dysfunction in nine individuals recruited from metabolic centers in six countries. In most individuals,
we identified biallelic frameshift variants in the molybdopterin binding (MPTb) domain, located upstream of the FADS domain. Inas-
much as FADS is essential for cellular supply of FAD cofactors, the finding of biallelic frameshift variants was unexpected. Using RNA
sequencing analysis combined with protein mass spectrometry, we discovered FLAD1 isoforms, which only encode the FADS domain.
The existence of these isoforms might explain why affected individuals with biallelic FLAD1 frameshift variants still harbor substantial
FADS activity. Another group of individuals with a milder phenotype responsive to riboflavin were shown to have single amino acid
changes in the FADS domain. When produced in E. coli, these mutant FADS proteins resulted in impaired but detectable FADS activity;
for one of the variant proteins, the addition of FAD significantly improved protein stability, arguing for a chaperone-like action similar to
what has been reported in other riboflavin-responsive inborn errors of metabolism. In conclusion, our studies identify FLAD1 variants as
a cause of potentially treatable inborn errors of metabolism manifesting with MADD and shed light on the mechanisms by which FADS
ensures cellular FAD homeostasis.Introduction
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Figure 1. FLAD1 Variants and Gene and Protein Structure
(A) Pedigrees of the investigated families (F1–F7) with recessively inherited FLAD1 variants. Affected individuals are indicated by closed
symbols.
(B) Gene structure with exons and introns shows the localization of the investigated gene variations (homozygous variants are under-
lined). Met residues located upstream of the FADS domain are presented in yellow with their corresponding protein positions with
(legend continued on next page)
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located in the cytosol or compartmented in the cellular or-
ganelles, where they ensure the functionality of mitochon-
drial electron transport, the metabolism of fatty acids,
some amino acids, choline, and betaine, the synthesis of
protoporphyrin, and the metabolism of vitamins B6, B9,
and B12.2–6
Riboflavin cannot be synthesized in humans and must
therefore be obtained as a nutrient via intestinal absorp-
tion. Riboflavin is transported into the bloodstream and
taken up by target cells by the human riboflavin trans-
porters (RFVTs). Three RFVTs (RFVT1, RFVT2, and
RFVT3), each differing in tissue-specific presence, have
been identified thus far and assigned to a new solute carrier
family named SLC52.4Within cells, riboflavin is converted
into FMN by riboflavin kinase (RFK), and FMN is then con-
verted into FAD by FAD synthase (FADS), previously
known as FAD synthetase or FMN:ATP adenylyltransfer-
ase.7,8 FADS is the product of FLAD1 (MIM: 610595),
which according to the UCSC Genome Browser encodes
two transcripts resulting in proteins with an intact FADS
domain. Those two transcripts have been characterized
in detail;7–12 a longer isoform derives from a large exon 1
and has the potential to encode FADS1 with a predicted
mitochondrial targeting sequence (MTS). In a shorter iso-
form, exon 1 is interrupted by an additional intron. This
leads to usage of a downstream ATG start codon at position
98 of the longer transcript, resulting in FADS2.13 Both
FADS proteins contain an N-terminal molybdopterin bind-
ing (MPTb) domain, which has been shown to have FAD
hydrolase activity,10 and a C-terminal 30-phosphoadeno-
sine 50-phosphosulfate (PAPS) reductase domain. This sec-
ond domain is sufficient to catalyze FAD synthesis.11
Therefore, it is here named the FADS domain. All recombi-
nant FADS produced up to now exhibit the ability to bind
FAD, the product of their activity, tightly but not cova-
lently.9 FAD release from FADS is likely to be tightly
controlled and presumably requires well-defined condi-
tions, including a correct redox state.9,12 FAD (or as
recently proposed, catalytically active FADS enzyme) binds
to apoproteins and chaperones their folding into stable
and functional flavoenzymes.14–19 Accordingly, several
studies have shown that a number of flavoproteins, and
in particular mature mitochondrial acyl-CoA dehydroge-
nases, undergo fast degradation under depletion of
riboflavin or flavin cofactors.20–23 The biochemistry of
riboflavin deficiency, with elevated multiple acylcarnitines
and urine organic acids, resembles that seen in individuals
who suffer from multiple acyl-CoA dehydrogenase defi-
ciency (MADD [MIM: 231680]) or glutaric aciduria type 2
and have genetic defects in three genes encoding two en-
zymes, electron transfer flavoprotein (ETF) and electronrespect to isoform 1 (GenBank: NM_025207.4). Isoforms 1 and 2 are r
intact and active FADS domain. The protein structure highlights the
consequences of the identified FLAD1 mutations include the fram
acid changes in a region of the FADS domain, which is highly co
conserved across all species are highlighted in dark blue.
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enzymes functionally link the acyl-CoA dehydrogena-
tion reactions to ATP production by delivering their
electrons to coenzyme Q10 and further on to complex III
in the respiratory chain.24 Riboflavin-responsive forms
of MADD leading to improvement in biochemical and
clinical symptoms after high doses of riboflavin treat-
ment were first explained by missense variants in
ETFDH (MIM: 231675)25–29 and more recently by variants
in the riboflavin transporter genes (SLC52A1 [MIM:
607883], SLC52A2 [MIM: 607882], and SLC52A3 [MIM:
613350]),30–32 as well as in the mitochondrial FAD trans-
porter gene (SLC25A32 [MIM: 610815]).33
In this study, we describe individuals who are from seven
unrelated families and have FLAD1 variants causing
MADD and a disturbed riboflavin metabolism. The
affected individuals presented with muscle symptoms
and multiple-respiratory-chain deficiency. Depending on
the FLAD1 genotype, some responded to riboflavin
treatment.Subjects and Methods
Subjects
Subjects (S1–S7) from seven unrelated families (F1–F7 in Figure 1A)
recruited from medical centers located in Australia, Finland, Italy,
Austria, Turkey, and France were enrolled in the current project.
All studies were completed according to local approval by institu-
tional review boards. Informed consent for participation in this
study was obtained from the parents of all investigated subjects
in agreement with the Declaration of Helsinki and approved by
the ethical committees of the centers participating in this study,
where biological samples were obtained.Genetic Analyses
For subjects S4a and S5, whole-exome sequencing (WES) was per-
formed in genomic DNA by AROS Applied Biotechnology AS with
Illumina’s TruSeq DNA Sample Prep Kit and Exome Enrichment
Kit on the Illumina HiSeq 2000 platform (for S5)34 or with
SureSelect Human All Exon 50Mb V5 Kit (Agilent) on a HiSeq
2500 system (Illumina) (for S4a).35,36 The remaining affected indi-
viduals were investigated by sequencing of candidate genes associ-
ated with fatty-acid oxidation and/or mitochondrial disorders,
including FLAD1 and other genes involved in riboflavin uptake
or metabolism. For subjects S1a, S2, and S3, Sanger sequencing
of the target genes listed in Table S1 was performed as described
previously.37,38 For subject S6, a customized gene panel39 (TruSeq
Custom Amplicon, Illumina) containing 200 genes associated
with mitochondrial disorders, including the genes listed in Table
S1, was used for library preparation; then, samples were analyzed
by a MiSeq system (Illumina). For subject S7, a panel of 17 genes
(Table S1) was analyzed with a targeted resequencing approacheported in the UCSC Genome Browser as transcripts possessing an
MPTb domain in violet and the FADS domain in orange. Protein
eshift variants located in the MPTb domain and the two amino
nserved among eukaryotic species. Amino acid residues that are
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by Ion AmpliSeq technology (Life Technologies) on a PGM
analyzer (Life Technologies). All identified variants and their
segregation in the affected families were validated by Sanger
sequencing.Skeletal-Muscle and Liver Homogenates and
Fibroblast Cultures
Muscle biopsy specimenswere obtained from seven subjects, and a
post-mortem liver specimen was obtained from individual S5.
Homogenization and preparation of mitochondrial fractions
were performed according to standard procedures. Primary human
dermal fibroblasts from subjects S1a, S2, and S4a and healthy
control individuals were cultivated until confluent at 37C and
5% (v/v) CO2 in RPMI-1640 media (Lonza) with 10% FCS,
2 mmol/L L-glutamine (Sigma-Aldrich), and 1% penicillin and
streptomycin (Sigma-Aldrich).Histological and Respiratory-Chain Analyses
Histological analyses andmeasurements of respiratory-chain func-
tion were performed via polarographic and spectrophotometric
analyses as previously described.25,40SDS-PAGE and Immunoblotting
Liver tissue was homogenized with a potter-type homogenizer on
ice in buffer (250 mmol/L sucrose, 50 mmol/L Tris-HCl [pH 7.4],
5 mmol/L MgCl2, EDTA-free protease inhibitor cocktail, and 1%
Triton X-100), and frozen fibroblast pellets were lysed in a
buffer containing 50 mmol/L Tris-HCL (pH 7.8), 5 mmol/L EDTA
(pH 8.0), 1 mmol/L DTT, 10 mg/mL Aprotinin (Sigma-Aldrich),
1 mg/mL trypsin inhibitor (Roche) in 10 mL, and 1% Triton
X-100. Aliquots of total liver protein (50–100 mg) were loaded
on 14% SDS-PAGE gels, and 20 mg fibroblast protein lysate was
loaded on Criterion GGX Stain-Free Precast Gels (Bio-Rad) and
transferred to polyvinylidene difluoride membranes. Membranes
were probed with human anti-FLAD1 antibody (fibroblasts:
HPA028563, Sigma-Aldrich; liver: ab95312, Abcam) and anti-
GAPDH (sc25778, Santa Cruz). Detected proteins were visualized
with the ECL Plus Western Blotting Detection System (GE
Healthcare).Mass Spectrometry to Confirm the Identity of
Anti-FADS Gel Bands
80 mg of total protein from control fibroblasts was extracted
and separated by SDS-PAGE as described above. The bands of
interest (~60, 50, 37, 32, and 27 kDa) were excised and processed
by an in-gel trypsin-digestion protocol as previously described.41
Selected reaction monitoring (SRM) was performed as previ-
ously described.42 Peptide selection, method development, and
data analysis were performed with the software Skyline.43
Five FADS peptides passed selection criteria based on detectability
and FADS uniqueness (checked in the whole human proteome,
UniProt version 2012_06_19, containing 20,202 reviewed se-
quences), and these five FADS peptides were analyzed by
liquid chromatography coupled with the TSQ Vantage Triple
Quadrupole Mass Spectrometer (Thermo Fisher Scientific). Four
or more transitions were detected for each peptide, and syn-
thetic isotopically labeled tryptic peptides (SpikeTide from JPT
Peptide Technologies) were added to each sample for quality
assurance. The list of peptides and transitions can be found in
Table S2.The AmericMeasurements of FAD Synthesis Rate and Flavin
Content
For investigating different fractions of EDTA blood from subject
S4a, plasma, mononuclear cells, and enriched erythrocytes puri-
fied by Ficoll gradient centrifugation, 50 ml of each was mixed
with 375 ml of 10% trichloroacetic acid and 75 ml of water. After in-
cubation on ice for 5 min and centrifugation at 13,000 3 g for
5 min, the supernatant was extracted with equal amounts of di-
ethyl ether twice, and 100 ml was applied to high-performance
liquid chromatography (HPLC) separation on a reversed-phase
column (Agilent, Eclipse Plus C18, 5 mm, 4.6 3 150 mm) for
measuring riboflavin, FMN, and FAD.
Flavin content in muscle homogenate from subject S5 was
measured by HPLC with a reverse-phase C18 column and fluores-
cence detection (excitation and emission wavelengths of 470 and
530 nm, respectively) according to the previously described
method.44 200 ml of muscle homogenate was mixed with 500 ml
methanol and centrifuged, and the supernatant was injected for
HPLC analysis (mobile phase: 50 mmol/L NaH2PO4 and 13%
acetonitrile [pH 2.9]; flow rate ¼ 1.2 mL/min).
For measurements in fibroblast cells, the frozen cells were re-sus-
pended in 150 ml lysis buffer (50 mmol/L Tris-HCl [pH 7.5], 1%
Triton X-100, 5 mmol/L b-mercaptoethanol [2-ME], 1 mmol/L
NaF, 0.1 mmol/L PMSF, and 13 protease-inhibitor cocktail) and
passed through a 26G needle. After incubation for 30 min on
ice, the cell suspension was centrifuged at 13,000 3 g for 10 min
at 4C, and the supernatant was recovered as cell lysate. Ribo-
flavin, FMN, and FAD were measured in neutralized perchloric
acid extracts of cell lysates (0.2 mg) by HPLC as previously
described.45–48 Separation was achieved with a Gilson HPLC sys-
tem, including a model 306 pump and a model 307 pump equip-
ped with a FP-2020 Plus Jasco Fluorescence Detector and uniPoint
software. Quantitative determination of riboflavin, FMN, and FAD
was carried out with a calibration curve made in each experiment
with standard solutions diluted in the extraction solution. The
rate of FAD synthesis was measured at 37C in 500 ml of 50 mM
Tris-HCl (pH 7.5) in the presence of 0.08 mg cell lysate, 1 mmol/L
FMN, 5 mmol/L ATP, and 5 mmol/L MgCl2. At the appropriate
time, 100 ml aliquots were taken, extracted with perchloric acid,
and neutralized. Riboflavin, FMN, and FAD were analyzed with
HPLC (see above).qRT-PCR and Transcriptome Analysis
Total RNA was isolated according to the TRIzol Reagent protocol
(Ambion) or with the RNeasy Plus Mini Kit (QIAGEN). The quality
of the RNA was determined with the Agilent 2100 BioAnalyzer
(RNA 6000 Nano Kit, Agilent). cDNAwas synthesized from subject
S2’s RNA with the iScript cDNA Synthesis Kit (Bio-Rad), and the
c.1588C>T genotype was assessed by sequencing.
qRT-PCR analysis (iQ SYBR Green Supermix, iCycler, Bio-Rad) of
subject S4a’s fibroblast RNA (TRI Reagent, Molecular Research
Center), treated with DNase (TURBO DNase, Thermo Fisher),
was performed with oligo-dT-amplified cDNA (Maxima Reverse
Transcriptase, Thermo Fisher) with a set of primers spanning all
coding regions of FLAD1 (Figure S1). Threshold cycles (Ct) were
normalized (DCt) to housekeeping genes HPRT (GenBank: NM_
000194.2; MIM: 308000) and RPL27 (GenBank: NM_000988.3;
MIM: 607526), and the expression of PCR products was compared
to that of control fibroblasts (DDCt).
For transcriptome analysis, quantitative library preparation and
enrichment were performed as described in Haack et al.49 RNAan Journal of Human Genetics 98, 1130–1145, June 2, 2016 1133
libraries were assessed for quality and quantity with the Agilent
2100 BioAnalyzer and the Quant-iT PicoGreen dsDNA Assay Kit
(Life Technologies) and sequenced as 100 bp paired-end runs on
an Illumina HiSeq 2500 platform. Sashimi plots were used for
quantitative visualization of splice junctions of their alignment
data in the Integrative Genomics Viewer.50Lentiviral Gene Expression
The wild-type (WT) sequence of isoform 2 (GenBank: NM_
201398.2) was obtained as a plasmid from DNASU
(HsCD00039838). Shorter FLAD1 transcripts coding for FADS pro-
teins starting at methionine 268 (Met268) or methionine 355
(Met355) were amplified from a human control cDNA and cloned
into the pLenti6.3/V5-TOPO TA Cloning Kit (Invitrogen) for pro-
duction in human fibroblasts.36 The following primers were used:
50-CGCCATGAAGGGACTATTCC-30 (forward Met268), 50-CGCCA
TGCCCAACGCTGTGG-30 (forward Met355), and 50-TCATGTG
CGGGAGTTCCGCT-30 (reverse).Biophysical Studies of Recombinant 6His-p.Ser495del
and 6His-p.Arg530Cys FADS2
Site-Directed Mutagenesis
The coding region for human FADS isoform 2 (FADS2) was ampli-
fied as previously described.7 The Ser495 deletion and the
p.Arg530Cys substitution were obtained via overlap-extension
PCR12 with the following primers: 50-ATCTGGGATTTTCTGTGT
CAGCTGTTTGTC-30 (forward) and 50-GACAAACAGCTGACACAG
AAAATCCCAGAT-30 (reverse) for p.Arg530Cys and 50-TGACCC
CTACTGTAGCCTCTGCCCTTTCAGCCCCACTGAC-30 (forward)
and 50-AGAGGCTACAGTAGGGGTCAGTCCGGCGGGTGCCC-30
(reverse) for the Ser495 deletion.
The PCR products were purified, digested with EcoRI and XhoI,
and ligated into the pH6EX3 expression vector as previously
described.9 The resulting recombinant plasmid carried the extra
N-terminal sequence MSPIHHHHHHLVPRGSEASNS.
Production and Purification of Recombinant 6His-Ser495del and
6His-p.Arg530Cys FADS2
Protein production in Rosetta (DE3) cells and purification of WT
or mutant FADS2 were carried out as described previously.9
Where indicated, the WT and variant proteins were incubated
with a 2.5-fold molar excess of FAD at 4C overnight, and the
free cofactor was eventually removed on a PD10-column run in
40 mmol/L HEPES/Na and 5 mmol/L 2-ME (pH 7.4).
Protein Concentration and Measurements of FAD Saturation
Protein concentration was measured by the Bradford method
with BSA as a standard. In an alternative procedure, the con-
centration of the purified FADS2 was estimated by absor-
bance spectra as previously described9 with the use of ε280
(56,435 mM1 $ cm1 and 0.998 mg/mL1 for the WT protein;
55,810 mM1 $ cm1 and 0.997 mg/mL1 for 6His-p.Ser495del
FADS2; and 56,435 mM1 $ cm1 and 0.999 mg/mL1 for 6His-
p.Arg530Cys FADS2) as calculated from the protein sequence
with the ExpasyProtParam tool. The degree of FAD saturation
(i.e. the ratio of FAD to protein monomer) was calculated from
the spectra as previously described.9
Measurements of FAD Synthesis Rate
The different fluorescence properties of FAD and FMN were ex-
ploited for measuring the rate of FAD synthesis. Fluorescence
time courses (excitation at 450 nm and emission at 520 nm) were
followed in a LS50 Perkin Elmer spectrofluorometer. FAD and
FMN fluorescence were calibrated with standard solutions, whose1134 The American Journal of Human Genetics 98, 1130–1145, Juneconcentrations were calculated with ε450 ¼ 12.2 mM1 $ cm1 for
FMN and 11.3 mM1 $ cm1 for FAD. The rate of FAD synthesis
(nmol FAD $ min1 $ mg protein1) was calculated from the rate
of decrease in fluorescence, measured as the tangent to the initial
part of the experimental curve. For activitymeasurements, purified
protein fractions (10 mg protein as a monomer, unless other-
wise indicated) were incubated at 37C in 2 ml of 50 mol/L Tris-
HCl (pH 7.5) containing 5 mmol/L MgCl2, 2 mmol/L FMN,
100 mmol/L ATP, and additional reagents as appropriate.
Limited Proteolysis with Trypsin
WT and mutant FADS2 proteins with or without incubation
with a molar excess of FAD were used for testing the susceptibility
to trypsin digestion. Samples (10 mg) were incubated with or
without 0.015 mg/mL trypsin (bovine pancreas trypsin, T8003,
Sigma-Aldrich) at 0C in 40 mmol/L HEPES/Na and 5 mmol/L
2-ME (400 mL). Aliquots of 2.5 mg protein were sampled at
different time points, and the reaction was stopped by the
addition of 0.3 mg/mL of soybean trypsin inhibitor (T9003,
Sigma-Aldrich). As an internal standard for the quantity of
loaded protein in the gel, BSA (1 mg) was also added to the
loading buffer solution. The products of the proteolysis reaction
were separated by 12% SDS-PAGE and electro-transferred onto
a nitrocellulose membrane with a Trans-Blot SD Semi-Dry
Electrophoretic Transfer Cell (Bio-Rad). The immobilized pro-
teins were incubated for 3 hr with a 3,000-fold dilution of a
polyclonal antiserum against FADS.13 The bound antibodies
were visualized with the aid of secondary anti-rabbit IgG anti-
bodies conjugated with alkaline phosphatase (1:3,500 dilution).
Quantitative evaluation of immuno-reactive protein bands was
carried out by densitometric analysis with ImageLab software
5.1 (Bio-Rad).Statistical Analysis
Statistical analysis was performed with the Poisson test for deter-
mining the number of loss-of-function (LOF) variants in FLAD1
and with the Student’s t test for pairwise comparisons of means
in Tables 2, 3, and 4. A p value of<0.05 was considered statistically
significant (*p < 0.05, **p < 0.01, ***p < 0.001).Results
Metabolic research centers from Australia, Austria,
Denmark, England, Finland, France, Germany, Italy, and
Turkey independently achieved and subsequently shared re-
sults from candidate-gene or WES analysis on families and
individuals affected by riboflavin-responsive MADD and/
or a suspected mitochondrial respiratory-chain disorder
(Table 1). As a result of this collaborative effort, from seven
unrelated families (F1–F7 in Figure 1A) we identified nine
affected individuals harboring recessive mutations in one
gene, FLAD1 (GenBank: NM_025207.4), coding for FADS.
Detailed case reports are available in the SupplementalNote.Genetic Analyses
In family F1, both siblings (S1a and S1b) were found to
carry a homozygous mutation resulting in an in-frame
deletion of serine 495 (c.1484_1486delCCT [p.Ser495del])
in the FADS domain. Individuals S2 and S3 were
found to carry the same missense mutation, c.1588C>T2, 2016
Table 1. Pre-treatment Genetic, Clinical, Biochemical, and Histopathological Findings in Individuals with FLAD1 Variants
ID Sex Consanguineous
FLAD1 Variants
(GenBank:
NM_025207.4)
FADS1 Variants
(GenBank:
NP_079483.3)
Affected
Domain
Age of
Onset Status
Responsive
to Riboflavin
Increased
Blood
Acylcarnitinesa
Elevated
Organic Acidsa
Muscle Investigations
Respiratory-
Chain
Activitiesb
Other
Mitochondrial
Enzyme
Activities Histology
S1a F yes c.[1484_1486delCCT];
[1484_1486delCCT]
p.[Ser495del];
[Ser495del]
FADS 32 hr died at
3 days
NT C5, C8, C14,
C5-DC
ethylmalonic,
adipic, suberic,
and
dehydrosebacic
acids,
hexanoylglycine
within
control
range
NR vacuoles in
muscle fibers
(EM not done)
S1b M yes c.[1484_1486delCCT];
[1484_1486delCCT]
p.[Ser495del];
[Ser495del]
FADS 3 months alive at
22 years
yes C4 ethylmalonic
and
methylsuccinic
acids
NR NR NR
S2 F no c.[568_569dupGC];
[1588C>T]
p.[Val191Glnfs*10];
[Arg530Cys]
MPTb (fs),
FADS
20 years alive at
44 years
yes C8, C10, C10:1 ethylmalonic
and glutaric
acids, lactate
CIIY, CIIIY,
CIVY
CS[ lipid-storage
myopathy,
faint COX
staining
S3 F no c.[836delT];
[1588C>T]
p.[Phe279Serfs*45];
[Arg530Cys]
MPTb (fs),
FADS
44 years alive at
56 years
yes C5, C8, C10,
C10:1, C14
ethylmalonic
acid,
tiglylglycine
CIþIIIY,
CIIþIIIY
CS[ lipid-storage
myopathy,
muscle beta
oxidation (C4:
132%; C8:
15%; C16:
56%)
S4a F yes c.[526_537delinsCA];
[526_537delinsCA]
p.[Ala176Glnfs*8];
[Ala176Glnfs*8]
MPTb (fs) 4 months alive at
8 years
yes C4, C6, C8,
C10, C14,
C14:1, C14:2,
C16:1, C18,
C18:1, C18:2
adipic, suberic,
ethylmalonic,
and
methylsuccinic
acids, ketosis
CIY, CIIY PDHY lipid-storage
myopathy
S4b F yes c.[526_537delinsCA];
[526_537delinsCA]
p.[Ala176Glnfs*8];
[Ala176Glnfs*8]
MPTb (fs) 8 months died at
16 years,
2 months
discontinued
(side effects)
normal or
C4-OH, C5,
C6, C8, C10,
C14:1, C16:1
NR NR NR NR
S5 M yes c.[401_404delTTCT];
[401_404delTTCT]
p.[Phe134Cysfs*8];
[Phe134Cysfs*8]
MPTb (fs) 6 months died at
6 months
NT C3, C5, C6,
C8:1
adipic acid CIY, CIIþIIIY CS[ lipid-storage
myopathy,
faint COX
staining
S6 F no c.[324delG];
[498delC;508T>C]
p.[Arg109Alafs*3];
[Ser167Profs*20;
Phe170Leu]
MPTb (fs) birth died at
9 months
no NR NR CIY, CIIþIIIY CS[ lipid-storage
myopathy,
absent SDH
staining,
several NADH-
and COX-
negative fibers
(Continued on next page)
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Table 2. Rate of FAD Synthesis in Fibroblasts from Individuals
with FLAD1 Variants
ID Rate of FAD Synthesis (pmol/min/mg)
C1 4.37 5 0.61
C2 4.36 5 0.4
C3 3.66 5 0.38
S1a 2.05 5 0.59**
S2 1.57 5 0.7***
S4a 1.04 5 0.47***
Data represent the mean 5 SD of three to four independent cell lysates.
**p < 0.01, ***p < 0.001.T
a
ID S7 A
b
C
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e
fs
,
a
A
b
A
1136 The American Journal of Human Genetics 98, 1130–1145, June(p.Arg530Cys), affecting the FADS domain and a frame-
shift variant in exon 2 on the other allele. The four
additional individuals were all found to carry biallelic
frameshift variants in exon 1 or 2. Carrier testing showed
that each parent analyzed was heterozygous for one allele
(Figure 1A). None of the predicted LOF variants was pre-
sent in an in-house database with WES data from approx-
imately 6,000 individuals or in >120,000 alleles from the
Exome Aggregation Consortium (ExAC) Browser (accessed
January 2016). Only variants c.1588C>T (p.Arg530Cys)
and c.508T>C (p.Phe170Leu) were recorded in the ExAC
Browser; c.1588C>T was recorded as heterozygous three
times in 121,410 alleles, and c.508T>C was recorded as
heterozygous two times in 121,408 alleles. Of note, the
affected individuals can be distinguished by their symp-
toms and the identified FLAD1 variants (Table 1 and the
Supplemental Note). Whereas subjects S1b, S2, and S3
(who showed a milder clinical course and a remarkable
response to riboflavin) carried at least one allelic variant
that changes or deletes a single amino acid in the FADS
domain, subject S4a (who showed only a partial response
to riboflavin) and subjects S4b, S5, S6, and S7 (who had
an early onset and lethal disease) all carried two predicted
LOF variants affecting the MPTb domain.
FADS activity is expected to be essential for humanmeta-
bolism, and no other protein with analogous function has
been reported. Therefore, FLAD1 variants predicted to
result in complete LOF were unexpected.
Residual FADS Activity and Flavin Content in FLAD1
Mutant Cells
The mild increase in metabolites derived from deficient
multiple acyl-CoA dehydrogenases argues for only a partial
defect in FAD synthesis and levels (Table S3). In accordance
with this, mild but significant decreases in the rate of FAD
synthesis were measured in cultured fibroblasts derived
from the affected individuals, whose activity was 50%
(S1a), 38% (S2), and 25% (S4a) of that of control individ-
uals (Table 2). Analysis of flavin content in the same cell
extracts and in blood from S4a and S4b supported remain-
ing FADS activity in all investigated subjects and revealed
FAD, FMN, and riboflavin amounts within the control2, 2016
Table 3. FAD, FMN, and Riboflavin Quantification in Cellular and Mitochondrial Fibroblast Samples from Control and Affected Individuals
ID FAD FMN Riboflavin FAD/FMN Ratio
Cellular flavin content (pmol/mg) C1 111.7 5 2.8 13.3 5 1.4 2.65 0.5 8.5 5 0.7
C2 171.2 5 18.8 12.4 5 0.3 3.15 0.1 13.8 5 1.9
C3 105.8 5 6.9 13.0 5 0.0 2.15 0.6 8.2 5 0.5
S1a 82.3 5 8.6 11.7 5 0.8 2.15 0.8 7.0 5 0.2
S2 84.3 5 3.1 11.5 5 0.6 2.45 0.9 7.3 5 0.1
S4a 111.4 5 6.6 15.8 5 0.4 2.55 0.5 7.0 5 0.6
Mitochondrial flavin content (pmol/mg) C1 2,093 3.0 5 0.1 NT 697.7 5 24.0
C2 1,940 3.2 NT 606.3
C3 1,895 3.2 NT 592.2
S4a 1,310 5 70** 2.0 5 0.7 NT 655.0 5 195.7
For cellular flavin content, data represent the mean 5 SD of two independent cell lysates. NT, not tested. **p < 0.01.range but increased amounts of FMN in erythrocytes
(Table 3 and Figure S3). Only when enriched mitochon-
drial fractions from subject S4a’s fibroblasts were investi-
gated were amounts of FAD and FMN found to be slightly
but significantly reduced (Table 3). In accordance with
decreased availability of mitochondrial FAD, subject S4a’s
fibroblast samples had reduced amounts of ETFDH and
complex II, two mitochondrial dehydrogenases that use
FAD as a co-factor (Figure S4). The amount of FAD in a skel-
etal-muscle biopsy from S5 (who, like S4a, carried biallelic
frameshift variants in exon 2) was 145 nmol/L, slightly
below the control range (174–471 nmol/L). Whereas
reduced FADS activity in S1a and S2 can be explained by
missense mutations, the residual FADS activity and the
relatively high content of FAD in S4a and S5 suggest
alternative mechanisms that allow expression of func-
tional FADS from FLAD1 variants predicted to result in
complete LOF.
Immunoblot Analysis of FLAD1 Mutant Cells
In order to investigate the molecular consequences of the
identified FLAD1 variants, we performed immunoblot an-
alyses for FADS in cell extracts from cultured fibroblasts
(from S1a, S2, and S4a) or from liver tissue (from S5)
(Figure 2). Using antibodies recognizing the FADS C termi-
nus, containing the FADS domain, we detected a number
of bands, including three high-intensity bands that were
expressed in both fibroblast and liver tissue: ~60 and
~50 kDa bands corresponding to the expected mito-
chondrial (isoform 1 [FADS1]) and cytosolic (isoform 2
[FADS2]) proteins, respectively (Figure 1B), and a ~26 kDa
band. Mass spectrometry confirmed only the ~50 and
26 kDa bands to be FADS, and only peptides located down-
stream of the MPTb domain encoded by exon 2 were de-
tected in the 26 kDa band (Figure 2A and 2C). As predicted
by the identified variants, individuals S4a and S5, both ho-
mozygous for frameshift variants in exon 2, showed no
detectable FADS2. In contrast, subject S1a, homozygous
for a single amino acid deletion (p.Ser495del) in theThe AmericFADS domain, showed FADS2 amounts within the control
range. Notwithstanding, in subject S2, in whom one allele
is predicted to cause an amino acid change (p.Arg530Cys)
in the FADS domain and a late-onset riboflavin-responsive
MADD phenotype, immunoblot analysis also revealed
severely decreased amounts of FADS2. The observation
that all mutations affect only the FADS2 band argues for
unspecific cross-reactive signals at 60 and 26 kDa. None-
theless, the findings of unique FADS peptides in the
26 kDa band suggest that at least a minor amount of iso-
form(s) might add to the observed residual FADS activity.
A faint 26 kDa band was repeatedly observed in liver tissue
from S5, but not in control liver (Figure 2B), suggesting
that compensatory increases in FADS isoforms are masked
by unspecific signals in fibroblast cells (Figure 2A). How-
ever, because of the limited amount of liver tissue, we
were not able to verify the identity of the 26 kDa
band. Two shorter isoforms (isoform 3 [GenBank: NM_
00114891] and isoform 4 [GenBank: NM_001184892])
have been reported in RefSeq (accessed January 2016). It
is not likely that the 26 kDa protein corresponds to any
of these, because both short isoforms contain sequences
specific to the MPTb domain. This argues for alternative
mechanisms by which residual FADS activity is produced
in FLAD1 mutant cells.
Alternative FLAD1 Transcripts and Activation of
Downstream ATG Start Sites Might Rescue LOF
Variants
Because most of the investigated individuals carried frame-
shift variants in exon 2, we were interested in themutation
load of FLAD1. We therefore divided FLAD1 into two parts:
one 1,117 bp fragment covering exons 1 and 2 and coding
for the MPTb domain and a second 647 bp fragment
covering exons 3–7 and coding for the FADS domain.
Although the ExAC Browser records an equal distribution
of missense and synonymous variants among the first
(0.178 variants/bp) and second (0.156 variants/bp) parts
of the gene, it lists 47 alleles with predicted LOF variantsan Journal of Human Genetics 98, 1130–1145, June 2, 2016 1137
Table 4. Kinetic Properties of 6His-p.Ser495del, 6His-p.Arg530Cys, and WT FADS2
Forward Reaction 6His-p.Arg530Cys 6His-p.Ser495del WT
Km FMN (mM) 0.39 5 0.07 0.98 5 0.23*** 0.32 5 0.10
Km ATP (mM) 4.63 5 1.00* 8.02 5 2.23 8.10 5 1.37
Vmax (nmol$min
1$mg1) 7.95 3.7*** 10.2 5 1.6** 43.3 5 12.2
Mg2þ50 (mM) 0.04 5 0.02* 0.09 5 0.01 0.07 5 0.01
Data represent the mean 5 SD of three experiments. *p < 0.05; **p < 0.01, ***p < 0.001.affecting exon 1 or 2 and only two LOF variants affecting
exons 3–7. This significant accumulation of LOF variants
in exons 1 and 2 (47 LOF variants within 1,117 bp) rather
than in exons 3–7 (two LOF variants within 647 bp,
p¼ 107, Poisson test) suggests alternative mechanisms re-
sulting nonetheless in functional FADS.
It has been shown that the FADS domain alone, without
the MPTb domain, is able to mediate FADS activity.11
Because the frameshift variants affect the MPTb domain,
we speculated whether additional splice variants or a
re-initiation of translation using a downstream ATG
codon could encode an active FADS. A prerequisite for re-
initiation of translation would be a stable FLAD1 tran-
script. qRT-PCR analysis from subject S4a’s fibroblast
cells with frameshift variants on both alleles revealed
stable FLAD1 transcript levels, which were reduced only
by about 50% in comparison to control levels (Figure S1),
indicating that the transcripts were only partially
degraded by nonsense-mediated decay. Likewise, sequence
analysis of FLAD1 RT-PCR products amplified from indi-
vidual S2’s fibroblasts showed heterozygosity for the
c.1588C>T variant, indicating that the C allele containing
c.568_569dupGC in exon 2 was stably expressed (data not
shown).
The human FLAD1 transcript contains two in-frame
downstream ATG codons located between the frameshift
variants and the region encoding the FADS domain (Fig-
ures 1B and 3A). Theoretically, these truncated FADS pro-
teins, starting at Met268 or Met355, could be translated
from the variant FLAD1 transcripts and thereby ensure
cytosolic FAD synthesis. On the basis of the idea of trun-
cated products with an active FADS domain, three different
constructs were expressed in primary fibroblast cells from a
control individual: the full-length construct starting at
Met98, a second construct starting at Met268, and a third
construct at Met355. All of the FLAD1 constructs were ex-
pressed and resulted in stable proteins easily detected by
immunoblotting (Figure 3C). When analyzing FADS activ-
ity in cell extracts, we found that expression of the Met268
construct resulted in a FAD synthesis rate higher than that
of control cells (data not shown). These data support the
possibility that re-initiation of translation using an in-
frame ATG codon would result in a stable protein contain-
ing an active FADS domain. However, the Met268 and
Met355 proteins did not migrate with a mass similar to
that of any of the FADS bands detected by immunoblot1138 The American Journal of Human Genetics 98, 1130–1145, Juneanalysis of case and control fibroblasts, including the
26 kDa band (Figure 3C).
We next investigated the possibility of alternative tran-
scripts by analyzing RNA sequencing data generated from
two fibroblast samples (C1 and C3) or a whole-blood
RNA sample (C2). Figure 3A summarizes in Sashimi plots
all detected RNA splice variants. In both tissues, FADS2
(comprising exons 1a and 1b) represents the most abun-
dant transcript; the next most-abundant transcript is
missing exon 1a but still encodes the same cytosolic pro-
tein isoform of 54 kDa. In none of the investigated samples
did we find evidence of FADS1, which covers all of exon 1
and retains intron 1a, or isoforms 3 (GenBank: NM_
00114891) and 4 (GenBank: NM_001184892) reported in
RefSeq. These observations are in agreement with the
immunoblotting experiments (Figure 2). In control fibro-
blast C3, 27 out of 28 reads starting with exon 1a
continued in exon 1b; however, one paired read detected
a transcript variant covering exon 1a, including an ATG
codon directly connected in frame to the open reading
frame in exon 3 (isoform 5 in Figure 3A). Isoform 5,
missing exons 1b and 2, has the potential to encode a
26 kDa functional FADS missing the MPTb domain. In
addition, we found a substantial number (11) of mRNA
reads directly connecting exons 1a and 2 (whereas 114
reads connected exons 1b and 2). None of them included
the ATG codon in exon 1a. This isoform, now isoform 6,
is predicted to code for the FADS starting with Met268.
In order to validate the presence of isoform 6, we per-
formed an RT-PCR experiment by using primers specific
to exons 1a and 2. Unexpectedly, we found substantial
amounts of both isoforms 2 and 6 (Figure 3B). None of
the identified frameshift variants in the ExAC Browser or
the frameshift variants presented here, which are predicted
to be pathogenic considering isoforms 1 and 2, would
affect the FADS encoded by isoform 6. Immunoblot anal-
ysis using case and control fibroblasts failed to detect the
predicted FADS proteins starting with Met268 or Met355,
but it did identify a 26 kDa band containing two FADS pep-
tides located downstream of the MPTb domain (Figures 2
and 3C). The FADS uniqueness of these peptides to the hu-
man proteome, as confirmed by bioinformatics analyses,
strongly suggests that the 26 kDa band indeed contains
FADS (see Subjects and Methods). We speculate that the
26 kDa band is based on isoform 5 and/or a proteolytically
processed version of the Met268 isoform 6 and has an2, 2016
Figure 2. Analysis of FADS Proteins
(A and B) Protein extract from cultured fibroblasts (A) or a liver biopsy (B) were separated by SDS-PAGE and immunoblotted with poly-
clonal antibodies against the C-terminal end of the human FADS. Subjects (S1a, S2, S4a, and S5) and healthy control individuals (C1, C2,
C3, and C) are indicated on top of the gels. Purified human FADS2 is indicated by ‘‘hF.’’ Trihalo staining or GAPDH were used as loading
controls. The numbers (P1–P4) on the right side of the immunoblot in (A) correspond to FADS peptides detected by mass spectrometry
(illustrated in C). Bands marked with an asterisk represent non-specific anti-FADS antibody bindings as defined by mass spectrometry.
(C) The amino acid sequence of human FADS1 (GenBank: NP_079483.3) is shown in one-letter symbols. The MPTb domain and the
FADS domain are shaded in violet and orange, respectively, and the four Met residues upstream of the FADS domain are written in
bold, and their protein positions are indicated. Peptides selected as identifiers of FADS and for use in the mass-spectrometry analysis
are written in superscript and further listed below with their analysis number (P1–P5) and protein domain. The signal from peptide 5
was treated as a nonsignificant finding because it was detected at the boarder of the detection limit of the SRM analysis in all analyzed
gel bands. The analysis was performed on gel bands processed from two independent cell lysates, and each peptide mixture was injected
and analyzed by msass spectrometry twice.active FADS domain that allows residual FADS activity,
even in cells with frameshift variants.
FLAD1 Missense Variants and Responsiveness to
Riboflavin
Natural human FADS, a putative component of FAD deliv-
ery machinery, behaves as a FAD-binding protein.9 Sub-
jects S1b, S2, and S3 were all found to carry FADS proteins
(p.Ser495del and p.Arg530Cys) with a potentially altered
ability to bind to and deliver flavin cofactor to nascent
client apo-flavoenzymes, as well as altered stabilization re-
quirements. To investigate this further, we overproduced
His-tagged p.Ser495del and p.Arg530Cys mutant FADS2
proteins in E. coli and characterized protein stability and
activity with and without in vitro reconstitution with
FAD. As illustrated in Figure 4, purified variant p.Ser495del
and p.Arg530Cys FADS2 proteins showed higher sensi-
tivity to proteolytic degradation than did WT FADS2 (Fig-
ures 4A and 4C), indicating that these polypeptides are
less tightly folded and consequently are more susceptible
to degradation by cellular proteases. Spectrophotometric
analysis of the purified WT, p.Ser495del, and p.Arg530Cys
FADS2 proteins revealed that the p.Ser495del protein, but
not the p.Arg530Cys protein, contained less bound flavin
(Figures 4B and 4D). In accordance with previous studies
showing that WT FADS2 is able to bind free FAD,9
in vitro reconstitution with a molar excess of FAD resulted
in a fully cofactor-bound p.Ser495del protein and rescued
proteolytic degradation (Figures 4A and 4B). Supplementa-
tion of flavin in the p.Arg530Cys protein did not change its
spectrophotometric properties and did not increase resis-
tance to proteolytic degradation (data not shown).The AmericWhen fully saturated with a molar excess of FAD, both
mutant FADS2 proteins still showed severely less catalytic
activity than did the WT protein (Figure 5). These kinetic
studies suggest that even though in vitro reconstitution
with FAD can rescue the stability of the p.Ser495del pro-
tein, it cannot correct its maximum in vitro catalytic activ-
ity. Nevertheless, because of its increased Km value for
FMN (inset in Figure 4B), the p.Ser495del protein is ex-
pected to be more sensitive to physiological changes in
cellular amounts of riboflavin than the WT counterpart.
After identification of MADD or FLAD1 variants, ribo-
flavin treatment was initiated in subjects S1b, S2, S3, S4a,
and S6. In agreement with the expected molecular actions
from the in vitro studies, individuals S1b, S2, and S3
showed responsiveness to riboflavin in vivo, including
improvement of cardiac and muscular functions, some de-
creases in acylcarnitine species, and normalization of urine
organic acids (Table S3). Amild improvement of hypotonia
was observed in subject S4a, whereas no evident beneficial
effect was reported in subject S6.Discussion
We describe nine affected individuals from seven inde-
pendent families affected by MADD and/or multiple-
respiratory-chain deficiency and mutations in FLAD1,
which encodes the enzyme FADS. The individuals
show a metabolic myopathy with lipid storage and res-
piratory-chain deficiency, resembling what is seen in
individuals with ETFDH defects and a late-onset ribo-
flavin-responsive MADD,28 yet they do not exhibit thean Journal of Human Genetics 98, 1130–1145, June 2, 2016 1139
Figure 3. Alternative FLAD1 Transcripts and Their Predicted Products
(A) Analysis of transcriptome data for FLAD1 from two unrelated fibroblast control samples (C1 and C3) and one human blood sample
(C2) revealed several possible transcripts, summarized as Sashimi plots (bottom). Schematic diagram shows isoform transcript structures
with MPTb and FADS domains marked in violet and orange, respectively (top). The most abundant transcript (isoform 2) corresponds to
the sequence reported in RefSeq (GenBank: NM_201398.2) but has an alternative intron in exon 1 and lacks the predictedMTS. Isoforms
5 and 6 represent transcripts without exons 1b and/or 2, where the identified FLAD1 frameshift variants are located, but both are able to
express an active FADS domain. Isoform 5 can use the Met marked as M-X in the very beginning of the transcript, whereas isoform 6
utilizes Met268. In RNA from fibroblasts or blood, we did not identify a single transcript resulting in isoforms 1 (GenBank:
NM_025207.4), 3 (GenBank: NM_00114891), or 4 (GenBank: NM_001184892) as reported in RefSeq. Isoforms 3 and 4 are not shown.
(legend continued on next page)
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Figure 4. Characterization of Recombinant 6His-p.Arg530Cys and 6His-p.Ser495del FADS2 Proteins
(A and B) The trypsin sensitivity (A) and degree of FAD saturation (B) of 6His-p.Ser495del FADS2 are reported in comparisonwith those of
the same protein after reconstitution with a 2.5-fold molar excess of FAD. In (B), spectra of both 6His-p.Ser495del FADS2 purified in its
apoform (0.58 mg/mL protein concentration, dashed line) and the reconstituted holoform (0.64 mg/mL protein concentration, black
line) are reported.
(C and D) The trypsin sensitivity (C) and degree of FAD saturation (D) of 6His-p.Arg530Cys FADS2 are reported in comparisonwith those
of WT FADS2. In (D), spectra of both 6His-p.Arg530Cys FADS2 (0.44 mg/mL protein concentration, straight line) and WT protein
(0.5 mg/mL protein concentration, dashed line) are reported.
Trypsin sensitivity was analyzed by immunoblotting. The control represents protein treated under the same condition but in the absence
of trypsin (). The slower migration of the control band might reflect that the 6His tag is rapidly removed upon addition of trypsin. BSA
was added to the loading buffer as an internal standard. In the graph, the time course of the limited proteolysis is reported as a percentage
of the control amount (arbitrarily set to 100%). The degree of FAD saturation was estimated from the UV/Vis absorbance spectra.progressive neurological signs, involving motor, sensory,
or cranial neuronopathies that are seen in the more
recently identified individuals diagnosed with Brown-
Vialetto-Van Laere syndrome (MIM: 211530), involving
defects in RFVT-encoding genes.32,35,51–53 When investi-(B) PCR products of cDNA from control subjects and subject S4a con
provided in Figure S1). The primer pair is able to amplify either isofo
ucts, respectively.
(C) Immunoblot analysis of the different FADS isoforms (Met98, M
healthy control individual shows their stability and detectability by
comparison.
The Americgated, individuals with FLAD1 variants showed no hearing
or visual impairment, and their peripheral-nerve conduc-
tion velocity was normal. Typical clinical phenotypes
were hypotonia and swallowing and speech difficulties.
Scoliosis was reported in three individuals, and manyfirmed the presence of non-degraded FLAD1mRNA (all details are
rm 2 or isoform 6 of the transcript, resulting in 307 or 84 bp prod-
et268, and Met355) overproduced in fibroblasts derived from a
anti-FADS antibody. A control fibroblast sample (C) is shown for
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Figure 5. Kinetic Characterization of Re-
combinant 6His-p.Arg530Cys and 6His-
p.Ser495del FADS2 Proteins
The dependence of FMN concentration on
the rate of FAD synthesis catalyzed by WT
(0.17 nmol), 6His-Arg530Cys (0.17 nmol),
or 6His-Ser495del (0.18 nmol) FADS2. The
FAD synthesis catalyzed by WT FADS2 is
presented as open symbols. Mutant FADS
is presented as closed symbols. The rate of
FAD synthesis was measured in the pres-
ence of 100 mmol/L ATP and 5 mmol/L
MgCl2. v0 was measured by the initial rate
of fluorescence decrease (excitation at
450 nm and emission at 520 nm) and ex-
pressed in nmol FMN $ min1 $ mg1
mutant FADS2 (A) and as a percentage
of the Vmax value (set arbitrarily to
100%) (B). Data points are fitted according
to the Michaelis-Menten equation.developed respiratory insufficiencies or arrest. Cardiomy-
opathy was reported only in a single individual, and two
required pacemaker implantation because of tachycardia
or sudden cardiac arrest. Most subjects presented with dis-
ease in early infancy, and four died within the first year of
life or in late childhood. Four subjects are still alive, and
three (S1b, S2, and S3, aged 22, 44, and 56 years, respec-
tively) differ from the others because they have gene vari-
ants affecting a single amino acid in the FADS domain,
share a milder clinical course, and are responsive to treat-
ment with riboflavin.
The clinical heterogeneity is mirrored by an allelic series
of variants, including transcript-specific frameshift vari-
ants and variants affecting only a single amino acid. FAD
is an essential cofactor, and FADS is the only known
human enzyme catalyzing the synthesis of FAD from
FMN. The unexpected FLAD1 frameshift variants led us
to discover previously undescribed transcript isoforms.
FLAD1 codes for a protein consisting of MPTb and FADS
domains. All of the identified frameshift variants affect
the MPTb domain. Early in evolution, these two domains
appeared as separate proteins, encoded by two different
genes, whereas in mammals they appear as one protein
containing two domains.1 However, the FADS domain
was shown to function independently from the other
domain.11 Indeed, we have discovered FLAD1 isoforms
that code for only the FADS domain (isoforms 5 and 6 in
Figure 3). The existence of these isoforms might explain
why affected individuals with biallelic FLAD1 frameshift
variants still harbor substantial FADS activity (Table 2).
However, despite residual FADS activity, homozygous car-
riers of frameshift variants are affected, and their disease
seems more severe than that observed in individuals
harboring single amino acid changes in the FADS domain
(Table 1). This could be explained by at least four different
mechanisms. (1) the mRNA expression levels of FADS iso-
forms 5 and 6 were found to be low, and although we
did not find conclusive evidence of their protein products
in fibroblasts from case and control individuals, protein
mass spectrometry of the 26 kDa band supports their exis-1142 The American Journal of Human Genetics 98, 1130–1145, Junetence (Figures 2 and 3). Determining the exact identity of
the 26 kDa band will require further studies. (2) We only
studied blood and fibroblast transcriptomes, and we have
no information about the isoform expression pattern in
the affected (muscle) tissue. (3) Although, there might be
sufficient FADS activity, the isoforms lack the uncertain
but potentially important activity of the MPTb domain.
Indeed, it has been recently suggested that the MPTb
domain possess FAD hydrolase activity10 and might be
needed for optimal FAD release to apoproteins.9,12,54 Ad-
dressing this question will require more experiments.
(4) Finally, even though our protein and transcriptome
data do not support substantial expression of the mito-
chondrial FLAD1 isoform 1, the mitochondrial isoform
might be expressed in other tissues or in other experi-
mental conditions where direct interaction between
FADS and apoproteins is needed to ensure sufficient or
catalytically controlled flavinylation of mitochondrial pro-
teins.9,54 Loss of isoforms 1 and 2 could result in disturbed
subcellular distribution of FADS. Isoforms 5 and 6 do not
harbor a MTS. Although some polypeptides can reach
mitochondria without a cleavable MTS,55 the frameshift
variants in the MPTb domain most likely result in defi-
ciency of mitochondrial FADS. Mitochondrial biogenesis
and function in these cells would then depend on supply
from cytosolic FAD synthesis. In accordance with this
idea, cellular FAD amounts within or slightly below the
control range were observed in all investigated subjects.
Significant decreases in FAD content were found only in
enriched mitochondrial fractions from subject S4. More-
over, the lipid storage and decreased activity of respira-
tory-chain enzymes in muscle homogenates from several
individuals (Tables 1, S4, and S5) points specifically to a
mitochondrial defect. In subject S4a, this was accompa-
nied by decreased amounts of ETFDH and the SDHA flavo-
component of complex II (Figure S4). Similarly, we would
expect amounts of other mitochondrial flavoproteins,
such as acyl-CoA dehydrogenases, to be decreased as
well.20–23 Even though this was not investigated, all re-
ported individuals with variant FLAD1 genotypes showed2, 2016
MADD or ethylmalonic and/or adipic aciduria (Tables 1
and S3), which argues for amore general impairment in fla-
vinylation of mitochondrial proteins under these condi-
tions. Decreased activity of complex II combined with
MADD biochemistry was also observed in a recently re-
ported subject with riboflavin-responsive exercise intoler-
ance due to a defect in mitochondrial FAD transport.33
Variants affecting only a single amino acid were detected
in four families. The c.508T>C (p.Phe170Leu) missense
variant identified in F6 in cis with a frameshift variant
most likely does not contribute to the FADS deficiency.
In families F2 and F3, we discovered a c.1588C>T
(p.Arg530Cys) missense variant, and in a family F1, we
found a 3 bp deletion (c.1484_1486del [p.Ser495del]);
both of these affect the FADS domain. In vitro studies
demonstrated that these variants result in impaired but
detectable FADS activity (Figure 5). At least for the deletion
variants, we could show that incubation with a molar
excess of FAD significantly improved protein stability
(Figure 4), arguing for a chaperone-like action of FAD,
similar to what has been reported in a number of
other metabolic disorders caused by gene variations
(mainly of the missense type) in proteins using FAD as a
cofactor.15–19,56,57 Concluding on the effectiveness of ribo-
flavin treatment in individuals with different types of
FLAD1 variants will require further in vitro studies of
FLAD1 genotypes and a larger group of individuals with
longer follow up. However, because there are no reported
side effects of riboflavin, all FLAD1-defective individuals
should initially be treated with riboflavin no matter their
type of mutation. The fatal outcome of the untreated
brother of an older sister (S1a), who responded to ribo-
flavin, stresses the importance of early diagnosis and treat-
ment in these disorders.
In conclusion, our studies have identified FLAD1 vari-
ants as a cause of potentially treatable myopathies
associated with MADD. This further establishes the hetero-
geneous etiology of MADD; some have ETF and/or ETFDH
variants, and others have defects in genes responsible for
cellular uptake of riboflavin, synthesis of flavin cofactors,
or mitochondrial FAD transport. Because there are still un-
solved cases of riboflavin-responsive MADD, it can be ex-
pected that the list of involved genes will still grow in
the future. Besides being important for the pathomechan-
ism of FLAD1 defects, our findings also stress that care
should be taken in the interpretation of predicted LOF var-
iants in large-scale sequencing projects. Sometimes LOF
variants affect only specific isoforms, and such findings
do not allow conclusions that the particular gene is not
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